VCM
CATX icon

Venator Capital Management’s Perspective Therapeutics CATX Stock Holding History

Venator Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-55,000
Closed -$170K – 29
2022
Q2 		$170K Buy
+55,000
New +$168K 0.26% 38

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TMWM
Taylor & Morgan Wealth Management Flint, Michigan $203M AUM 24.74% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Venator Capital Management's CATX Position: Q3 2022 in Review

Venator Capital Management sold out of Perspective Therapeutics (CATX) in Q3 2022, closing a stake of 55,000 shares — an estimated $170K sold.

Venator Capital Management first reported a position in CATX in Q2 2022 and held it in 1 quarter. The position peaked at $170K in Q2 2022. 35 funds tracked by Wall St. Rank hold CATX as of Q3 2022.

  • Venator Capital Management reported no remaining Perspective Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Venator Capital Management sold 55,000 Perspective Therapeutics shares in Q3 2022, an estimated $170K.
  • Venator Capital Management first reported a position in Perspective Therapeutics in Q2 2022 and held it in 1 quarter.
  • Venator Capital Management's Perspective Therapeutics position peaked at $170K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2022.

Based on Venator Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.